Yuanxin Liang, MD, PhD
Assistant Professor of PathologyCards
About
Research
Publications
2025
Invasive breast carcinoma in a patient with PHTS: a case report
Zhan H, Fischbach N, Lynch M, Liang Y, Krishnamurti U, Cohen P. Invasive breast carcinoma in a patient with PHTS: a case report. Diagnostic Pathology 2025, 20: 120. PMID: 41107919, PMCID: PMC12532417, DOI: 10.1186/s13000-025-01715-1.Peer-Reviewed Original ResearchConceptsPTEN hamartoma tumor syndromeAtypical ductal hyperplasiaHamartoma tumor syndromeTumor syndromeFamily historyBilateral palpable breast massesFocal atypical ductal hyperplasiaFamily history of cancerInvasive breast carcinomaPalpable breast massesEctopic breast tissueBloody nipple dischargeAxillary lymph nodesGermline pathogenic variantsHistory of cancerCase presentationWeInvasive carcinomaBreast carcinomaDuctal hyperplasiaMastectomy specimensNipple dischargeRight breastBenign papillomasMultiple biopsiesPapillary proliferationInfrequent HPV Infection in Colorectal Neuroendocrine Carcinoma: Molecular and Histologic Characteristics
Wang X, Zhong M, Zhang X, Liang Y. Infrequent HPV Infection in Colorectal Neuroendocrine Carcinoma: Molecular and Histologic Characteristics. Diagnostics 2025, 15: 2569. PMID: 41153242, PMCID: PMC12562367, DOI: 10.3390/diagnostics15202569.Peer-Reviewed Original ResearchHigh-risk human papillomavirusSmall cell neuroendocrine carcinomaCell neuroendocrine carcinomaColorectal neuroendocrine carcinomaNeuroendocrine carcinomaPlatinum-based chemotherapyHigh-risk HPVHigh risk human papillomavirus statusHigh-risk human papillomavirus testingAssociated with high-risk human papillomavirusOncogenic mutationsMethods:Molecular profilingResults:Rectal neuroendocrine carcinomaComprehensive molecular profilingOptimal treatment strategyLong-term survivorsHPV infectionAggressive tumorsP16 expressionHuman papillomavirusClinical outcomesLonger survivalSurrogate markerInterobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situAtypical ductal hyperplasiaCarcinoma in situSpindle-shaped nucleiAssociated with carcinomaIndividual histologic featuresHistological featuresInterobserver agreementDuctal hyperplasiaBreast pathologistsBiopsy casesCases of atypical ductal hyperplasiaLow-grade ductal carcinoma in situEpithelial cellsClinical follow-up dataLesion extentHistological analysisDiagnostic gray zoneMulti-institutional studyVariable interobserver agreementFollow-up dataModerate to substantial agreementDuct involvementHistologic reviewRadiological findingsEstrogen receptor conversion in bone, liver and lung metastases from breast cancer
Podany P, Zhan H, Ai D, Krishnamurti U, Liang Y. Estrogen receptor conversion in bone, liver and lung metastases from breast cancer. Pathology - Research And Practice 2025, 275: 156222. PMID: 40967162, DOI: 10.1016/j.prp.2025.156222.Peer-Reviewed Original ResearchER conversionPrimary tumorTumor gradeGrade of primary tumorAssociated with worse prognosisMetastasis to boneBreast cancer treatmentMetastatic sitesER-positiveMedian survivalTP53 mutationsLiver metastasesPR positivityPIK3CA mutationsReceptor conversionClinicopathological factorsLung metastasesWorse prognosisNo significant differenceTumor typesBreast cancerGenetic alterationsMetastasisPatient managementTumorPTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence
Zhan H, Antony V, Tang H, Theriot J, Liang Y, Hui P, Krishnamurti U, DiGiovanna M. PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence. Breast Cancer Research And Treatment 2025, 211: 441-447. PMID: 40063317, DOI: 10.1007/s10549-025-07660-3.Peer-Reviewed Original ResearchConceptsPten inactivating mutationsBreast cancerER+/HER2- tumorsRecurrent tumorsER+/HER2- breast cancer patientsInactivating mutationsAssociated with worse clinical outcomesTreatment historyER+/HER2- breast cancerTriple negative phenotypeBreast cancer recurrenceBreast cancer patientsHormone receptor lossResultsThe average timeHR+ tumorsDistant recurrenceHR statusER expressionRecurrent diseaseTumor histologyTumor recurrenceHER2 expressionHormone independencePatient ageClinicopathological characteristics
2024
Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer
Sun T, Golestani R, Zhan H, Krishnamurti U, Harigopal M, Zhong M, Liang Y. Clinicopathologic Characteristics of MYC Copy Number Amplification in Breast Cancer. International Journal Of Surgical Pathology 2024, 33: 59-64. PMID: 38839260, DOI: 10.1177/10668969241256109.Peer-Reviewed Original ResearchBreast cancerCopy number amplificationClinicopathological characteristicsAssociation with TP53 mutation. InAssociated with invasive ductal carcinomaEstrogen receptor (ER)-negativeDisease-free survival timeGene copy number amplificationC-myc immunostainingNon-amplified tumorsTP53 mutationsTriple-negative statusMetastatic breast cancerInvasive ductal carcinomaMYC protein overexpressionBreast cancer patientsTriple-negativeDuctal carcinomaClinicopathological featuresGenetic abnormalitiesClinical dataImmunohistochemical studiesCancer patientsProtein overexpressionSurvival timeHistopathology and its clinical correlation of liver biopsy in patients with treated autoimmune hepatitis
Korie U, Joldoshova A, Khandakar B, Zhang X, Liang Y. Histopathology and its clinical correlation of liver biopsy in patients with treated autoimmune hepatitis. Annals Of Diagnostic Pathology 2024, 73: 152333. PMID: 38820911, DOI: 10.1016/j.anndiagpath.2024.152333.Peer-Reviewed Original ResearchConceptsAutoimmune hepatitisCo-existing diseasesTransaminase levelsLiver biopsyHistological featuresClinical correlatesDuctular reactionPeriportal fibrosisDiagnosis of autoimmune hepatitisHepatocyte injuryUntreated autoimmune hepatitisModerate portal inflammationModerate lobular inflammationSteroid therapyInterface hepatitisSteroid treatmentAIH groupPortal inflammationTreatment resistanceClinical featuresLobular inflammationBiopsyPatientsInflammationInjury features
2023
Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review
Carrasco-Tenezaca F, Moreira-Dinzey J, Manrai P, Bearse M, Burela S, Podany P, Singh K, Pareja F, Zheng J, Muscato N, Liang Y, Zhan H, Krishnamurti U, Dolezal D, Wang J, Harigopal M. Breast Carcinoma With Tubulopapillary Features Has a Distinct Immunophenotypic and Molecular Signature: A Report of Two Tumors and Literature Review. International Journal Of Surgical Pathology 2023, 32: 1037-1045. PMID: 37908113, DOI: 10.1177/10668969231209780.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBreast carcinomaTubulopapillary featuresHuman epidermal growth factor 2 (HER2) expressionBreast cancer histologic subtypesNonmetastatic breast carcinomaTriple-negative profileHigh-grade nuclear featuresTriple-negative carcinomasHigh-grade featuresMetastatic breast carcinomaGrowth factor 2 expressionFactor 2 expressionReports of tumorsMicropapillary projectionsNeoadjuvant therapyHistologic subtypeWorse prognosisFirst tumorPoor prognosisAdditional tumorsInvasive carcinomaEstrogen receptorCarcinomaPathogenic variantsTumorsPrognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Mogica J, Tang H, Liang Y, Zhong M, Hui P, Harigopal M, Krishnamurti U, Fischbach N, Zhan H. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. The Breast 2023, 72: 103586. PMID: 37812963, PMCID: PMC10568274, DOI: 10.1016/j.breast.2023.103586.Peer-Reviewed Original ResearchConceptsHER2 IHC 3Human epidermal growth factor receptor 2Kaplan-Meier survival analysisHER2-IHC expressionPathologic complete responseResidual diseaseIHC 3Breast cancerIHC expressionSurvival analysisSuperior disease-free survivalEpidermal growth factor receptor 2Intensive adjuvant therapyPost-therapy surveillanceYale Cancer CenterDisease-free survivalGrowth factor receptor 2Recurrence-free survivalSingle institution experienceLow recurrence rateFactor receptor 2HER2 protein expressionAdjuvant trialsNeoadjuvant treatmentAdjuvant therapyHistology and clinical correlations in autoimmune hepatitis, primary biliary cholangitis, and autoimmune hepatitis-primary biliary cholangitis overlap syndrome
Liang Y, Khandakar B, Hao Y, Xiong Y, Liu B, Zhang X. Histology and clinical correlations in autoimmune hepatitis, primary biliary cholangitis, and autoimmune hepatitis-primary biliary cholangitis overlap syndrome. Annals Of Diagnostic Pathology 2023, 67: 152178. PMID: 37468373, DOI: 10.1016/j.anndiagpath.2023.152178.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisAutoimmune hepatitisOverlap syndromeHistological featuresAntibody positivityBiliary cholangitisAnti smooth muscle antibody positivityClinical correlatesAIH-PBC overlap syndromeDiagnosis of autoimmune hepatitisAntimitochondrial antibody positivityAIH-PBCInterface hepatitisUntreated patientsDuct damageTransaminase levelsClinical findingsPlasma cellsClinical dataLobular inflammationOS casesPortal tractsHepatitisSyndromeCholangitis